Sunday, May 17, 2015 3:15:35 PM
So after reading some of the recent GBLX filings more carefully I do not see where the article I cited, link below, can say... "Lazarus Management Co LLC, has filed to purchase 22.3% of Growblox shares. The move reflects Lazarus’s confidence in the growing cannabis company."
Here is the link to that article
http://www.journaltranscript.com/2015/05/growblox-sciences-inc-otcmktsgblx-announces-new-website-focusing-on-three-divisions/
What I see in the 8K filed on 4/30 is Lazarus selling their warrants back to GBLX for 40K and not exercising them. Any one following these events have any ideas? I see that GBLX says "temporarily reduce the warrant price". Why would Lazarus sell them back? for a penny? Is GBLX asking warrant holders to exercise or return? If so why?
From the 8K
In order to encourage the exercise of the Company’s B warrants, on February 12, 2015, the board of directors of the Company passed
a resolution to temporarily reduce, until April 30, 2015, the exercise price of such warrants from $2.00 per share to $0.20 per share, and the
holders of the B warrants were notified of such temporary exercise price reduction. As at April 29, 2015, B warrants to purchase 1,970,000
shares of company common stock were exercised at $0.20 per share, resulting in net proceeds of $394,000 to the Company. On April 30, 2015,
the Company’s board of directors extended to 5:00 PDT on May 15, 2015 the temporary voluntary reduction of the exercise price of the B
Warrants to $0.20 per share and notified the holders of the B Warrants .
On April 27, 2015, Lazarus Investment Partners LLLP and Lazarus Israel Investment Opportunities Fund, LLLP sold back to the
Company for $0.01 each, warrants to purchase 3,000,000 and 1,000,000 shares, respectively.
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10659512
Recent GBLX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/12/2024 09:39:05 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 10:07:34 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 10/10/2023 02:00:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/08/2023 08:15:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 06:31:48 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 08/02/2023 08:18:58 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 07/14/2023 08:12:47 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 06/30/2023 12:00:24 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM